Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes
University of Colorado, Denver
Summary
This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type 2 diabetes. This study aims to look at how well the medication works in people with type 1 diabetes. Semaglutide is not approved by the FDA to be used in this way. These procedures are considered to be experimental.
Eligibility
- Age range
- 18–49 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Age 18-49 years * 1\) T1D diagnosis defined as positive T1D-associated antibody(ies) or 2) a clinical diagnosis of T1D plus insulin requirement since diagnosis * Insulin pump or automated insulin delivery systems * Estimated glomerular filtration rate (eGFR) ≥ 45 ml/min/1.73m2 * Stable doses of drugs altering cardiovascular and renal function (e.g., Angiotensin-Converting Enzyme Inhibitor (ACEi), Angiotensin Receptor Blocker (ARB), statins, diuretics) * BMI 20-45 kg/m2 * Adequate contraceptive method for females Exclusion Criteria: * HbA1c \>9%, recent diabetic ketoaci…
Interventions
- DrugSemaglutide Pen Injector
Semaglutide injection
- DrugPlacebo
Semaglutide placebo injection
Locations (2)
- University of Colorado Anschutz Medical CampusAurora, Colorado
- University of Washington Medicine Diabetes Institute (UWMDI)Seattle, Washington